Liquid biopsy of extracellular vesicle biomarkers for prostate cancer personalized treatment decision
2022

Liquid biopsy for prostate cancer treatment decisions

Sample size: 1212 Commentary Evidence: moderate

Author Information

Author(s): Han Meng, Pang Bairen, Zhou Cheng, Li Xin, Wang Qi, Jiang Junhui, Li Yong

Hypothesis

Liquid biopsy of extracellular vesicle biomarkers can improve personalized treatment decisions for prostate cancer.

Conclusion

The study highlights the potential of liquid biopsy using extracellular vesicles to guide treatment decisions for prostate cancer patients.

Supporting Evidence

  • Liquid biopsy can detect biomarkers in a non-invasive way.
  • Extracellular vesicles can provide important information about tumor status.
  • The EPI test can help avoid unnecessary biopsies by accurately predicting cancer grades.

Takeaway

Doctors can use a simple urine test to find out if a man has a serious type of prostate cancer, which helps them decide if he needs a biopsy.

Methodology

The study discusses the use of a urine EV gene expression assay to differentiate between high-grade and low-grade prostate cancer.

Limitations

The clinical application of EV-based liquid biopsy faces challenges such as sample heterogeneity and the need for optimized isolation techniques.

Participant Demographics

The study involved 1212 subjects across three independent prospective multicenter clinical trials.

Digital Object Identifier (DOI)

10.20517/evcna.2021.20

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication